Lupin Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Lupin Limited - overview
Established
1968
Location
Mumbai, -, India
Primary Industry
Pharmaceuticals
About
Founded in 1968 and based in Mumbai, India, Lupin Limited operates as a pharmaceutical company that develops generic ophthalmic, dermatology and respiratory drugs.
Current Investors
Baring Private Equity Partners
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.lupin.com/
Verticals
Manufacturing
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
Lupin Limited - financials
| Fiscal Year Ended | Mar 31, 2012 | Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 70,829,100,000 | 96,413,000,000 | 112,865,700,000 | 127,700,100,000 | 142,084,700,000 | 174,943,300,000 | 158,041,500,000 | 167,181,800,000 | 153,747,600,000 | 151,629,600,000 | - | - | - |
| % Revenue Growth (YoY) | - | 36.1% | 17.1% | 13.1% | 11.3% | 23.1% | (9.7%) | 5.8% | (8.0%) | (1.4%) | - | - | - |
| EBITDA (USD) | 14,510,200,000 | 22,862,200,000 | 31,054,100,000 | 38,518,700,000 | 39,385,600,000 | 45,910,000,000 | 18,174,700,000 | 28,435,500,000 | 21,507,400,000 | 26,648,100,000 | - | - | - |
| Operating Income (USD) | 12,235,000,000 | 19,540,300,000 | 28,444,400,000 | 34,171,700,000 | 34,750,600,000 | 36,787,700,000 | 7,316,000,000 | 17,585,400,000 | 9,911,600,000 | 17,774,000,000 | - | - | - |
| Operating Margin | 17.3% | 20.3% | 25.2% | 26.8% | 24.5% | 21.0% | 4.6% | 10.5% | 6.4% | 11.7% | - | - | - |
| % EBITDA Margin | 20.5% | 23.7% | 27.5% | 30.2% | 27.7% | 26.2% | 11.5% | 17.0% | 14.0% | 17.6% | - | - | - |
| NET Income (USD) | 8,875,100,000 | 13,404,400,000 | 18,695,000,000 | 24,444,300,000 | 22,794,500,000 | 25,646,300,000 | 2,583,500,000 | 6,154,800,000 | (2,693,900,000) | 12,279,300,000 | - | - | - |
| % Net Margin | 12.5% | 13.9% | 16.6% | 19.1% | 16.0% | 14.7% | 1.6% | 3.7% | (1.8%) | 8.1% | - | - | - |
Lupin Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | Kyowa Pharmaceutical Industry Co., Ltd. | - | ||||||||
| PIPE | Completed | Lupin Limited | - | ||||||||
| Trade Sale | Completed | Medquímica Indústria Farmacêutica S.A. | - | ||||||||
| Add-on | Completed | Nanomi BV | - | ||||||||
| PIPE | Completed | Lupin Limited | - |
Displaying 1 - 5 of 7
Lupin Limited - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Member of the Board | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.